British scientists have begun clinical trials of the world's first vaccine against lung cancer. The patient was a 67-year-old resident of London, Janusz Racz. The vaccine was developed by BioNTech. The drug is based on mRNA technology, which activates the immune system to fight cancer cells. The injection is aimed at treating non-small cell lung cancer and provides minimal risks of damage to healthy tissue compared to traditional chemotherapy. For a long time, Janusz has been battling oncology. He began standard cancer treatment in May after his diagnosis and recently received the world's first vaccine, which is administered in minutes. Scientists say the results of the clinical trial will be known in six to 18 months. The first phase of human testing of the drug has begun at 34 research sites in the UK, USA, Germany, Hungary, Poland, Spain and Turkey. At the moment, 130 patients from different countries are waiting for the vaccination.